- Home
- ESAB vs ADPT Comparison
ESAB vs ADPT Comparison
Compare ESAB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | ADPT |
|---|---|---|
| Founded | 1904 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.5B |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESAB | ADPT |
|---|---|---|
| Price | $86.87 | $29.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $116.91 | $32.29 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $2,842,555,000.00 | $276,976,000.00 |
| Revenue This Year | $7.52 | $10.87 |
| Revenue Next Year | $9.14 | $21.02 |
| P/E Ratio | $48.42 | ★ N/A |
| Revenue Growth | 3.71 | ★ 54.77 |
| 52 Week Low | $62.74 | $12.00 |
| 52 Week High | $137.42 | $30.79 |
Technical Indicators
Market Signals| Indicator | ESAB | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 71.02 | 60.68 |
| Support Level | $82.55 | $24.02 |
| Resistance Level | $94.18 | $29.92 |
| Average True Range (ATR) | 4.34 | 1.82 |
| MACD | 2.20 | 0.40 |
| Stochastic Oscillator | 87.30 | 80.40 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.